Format

Send to

Choose Destination
Reprod Toxicol. 2019 Mar 5;86:1-13. doi: 10.1016/j.reprotox.2019.03.001. [Epub ahead of print]

Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis.

Author information

1
Terafar - Izmir Katip Celebi University Teratology Information, Training and Research Center, Izmir, Turkey; Izmir Katip Celebi University School of Medicine, Department of Pharmacology Izmir, Turkey.
2
The UK Teratology Information Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK. Electronic address: Jonathan.Richardson@nuth.nhs.uk.
3
Mothersafe, The Royal Hospital for Women, Sydney, New South Wales, Australia; School of Women's and Children's Health University of New South Wales, Australia.

Abstract

AIMS:

To investigate whether ondansetron use during pregnancy is associated with increased rates of major or subgroups of malformations.

METHODS:

PubMed/MEDLINE, Cochrane and Reprotox® databases were searched. Observational studies comprising an exposed and control group (healthy and/or disease-matched) were included.

RESULTS:

No significant increased risk for major malformations, heart defects, orofacial clefts, genitourinary malformations or hypospadias were identified in our primary analysis. A significant heterogeneity existed for isolated cleft palate. Elevated point estimates and altered statistical significances were present for some of the outcomes among secondary analyses.

CONCLUSIONS:

Ondansetron use during pregnancy was not associated with a significant increase in rate of major or selected subgroups of malformations in our primary analysis. However, results of the secondary analyses warrant the need for continued surveillance. These results may be reassuring for pregnant women in whom ondansetron use is clinically indicated since the absolute risks of possible concerns appear to be low.

KEYWORDS:

Birth defects; Congenital abnormalities; Hyperemesis gravidarum; Nausea and vomiting of pregnancy; Ondansetron; Pregnancy

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center